# Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin

> **NCT02420691** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 21 (actual)

## Conditions studied

- Advanced Digestive System Neuroendocrine Neoplasm
- Duodenal Neuroendocrine Tumor G1
- Functional Pancreatic Neuroendocrine Tumor
- Gastric Neuroendocrine Tumor
- Intermediate Grade Lung Neuroendocrine Neoplasm
- Low Grade Lung Neuroendocrine Neoplasm
- Nonfunctional Pancreatic Neuroendocrine Tumor
- Thymus Neoplasm

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Ribociclib

## Key facts

- **NCT ID:** NCT02420691
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-25
- **Primary completion:** 2019-06-05
- **Final completion:** 2019-06-05
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2020-10-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02420691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02420691, "Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02420691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*